Display options
Cite
Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73
Land, S. C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International journal of physiology, pathophysiology and pharmacology, 4(2), 59-73.
Land, Stephen C. "Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists." International journal of physiology, pathophysiology and pharmacology vol. 4,2 (2012): 59-73.
Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. Epub 2012 Jun 23. PMID: 22837805; PMCID: PMC3403564.
Copy Download .nbib Format: NLM
Share it on

Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. Epub 2012 Jun 23.

Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.

International journal of physiology, pathophysiology and pharmacology

Stephen C Land

Affiliations

  1. Centre for Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee Dundee, DD1 9SY, Scotland, UK.

PMID: 22837805 PMCID: PMC3403564

Abstract

BACKGROUND/AIMS: Chemokine signaling from airway epithelium regulates macrophage recruitment to the lung in inflammatory diseases such as asthma. This study investigates the mechanism by which the α-melanocyte stimulating hormone-derived tripeptide, KPV, and the agonist of the dominant melanocortin receptor in airway epithelium (MC3R), γ-melanocyte stimulating hormone (γ-MSH), suppress inflammation in immortalised human bronchial airway epithelium.

METHODS: TNFα and rhino syncitial virus (RSV)-evoked nuclear factor-κB (NFκB) signaling was measured in immortalised human bronchial epithelial cells (16HBE14o-) in response to KPV and γMSH. Cellular and systemic inflammatory signaling was measured by NFκB reporter gene and chemokine (IL8, eotaxin) secretion, respectively.

RESULTS: KPV and γMSH evoked a dose-dependent inhibition of NFκB, matrix metalloproteinase-9 activity, IL8 and eotaxin secretion. The KPV effect was associated with its nuclear import, IκBα stabilisation and suppressed nuclear translocation of YFP-tagged p65RelA. Competition assays revealed an interaction between KPV and the Imp-α3 binding site on p65RelA which may involve blockade of the importin-α armadillo domain 7 and 8. In contrast, the γMSH anti-inflammatory effect required MC3R whose apical expression occurred in epithelium distributed along the length of the respiratory tree in vivo.

CONCLUSION: KPV and γMSH respectively suppress NFκB signalling in airway epithelium by: i) inhibition of p65RelA nuclear import and, ii) epithelial MC3R activation. Melanocortin peptides therefore provide a robust mechanism for targeting airway inflammation in lung disease.

Keywords: KPV; MC3R; airway epithelium; asthma; chemokine signaling; inflammation; melanocortin receptor; α-melanocyte stimulating hormone-derived tripeptide; γ-melanocyte stimulating hormone (γ-MSH)

References

  1. J Biol Chem. 2005 Apr 22;280(16):15942-51 - PubMed
  2. PLoS One. 2010 Jul 14;5(7):e11598 - PubMed
  3. Trends Biotechnol. 1990 Jun;8(6):140-4 - PubMed
  4. Peptides. 2007 Oct;28(10):2016-22 - PubMed
  5. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L473-87 - PubMed
  6. Pulm Pharmacol Ther. 2008 Dec;21(6):866-73 - PubMed
  7. Neuroimmunomodulation. 1997 Jan-Feb;4(1):37-41 - PubMed
  8. Biochim Biophys Acta. 2008 Mar;1783(3):394-404 - PubMed
  9. Gastroenterology. 2008 Jan;134(1):166-78 - PubMed
  10. J Immunol. 1986 Oct 1;137(7):2232-6 - PubMed
  11. Endocr Rev. 2008 Aug;29(5):581-602 - PubMed
  12. Pharmacol Rev. 2004 Mar;56(1):1-29 - PubMed
  13. J Leukoc Biol. 1998 Jun;63(6):740-5 - PubMed
  14. J Biol Chem. 1990 May 25;265(15):8573-82 - PubMed
  15. EMBO J. 1989 Mar;8(3):797-804 - PubMed
  16. J Immunol. 2005 Oct 1;175(7):4806-13 - PubMed
  17. Biochem Biophys Res Commun. 1999 Sep 16;263(1):251-6 - PubMed
  18. J Biol Chem. 2003 Jul 25;278(30):28193-200 - PubMed
  19. J Invest Dermatol. 2002 Dec;119(6):1244-53 - PubMed
  20. Am J Respir Cell Mol Biol. 2011 May;44(5):716-24 - PubMed
  21. J Immunol. 2003 Jul 1;171(1):353-9 - PubMed
  22. J Leukoc Biol. 2000 Nov;68(5):693-9 - PubMed
  23. PLoS Comput Biol. 2009 Mar;5(3):e1000335 - PubMed
  24. Mol Cell Biol. 1989 Jun;9(6):2487-92 - PubMed
  25. Curr Protein Pept Sci. 2004 Dec;5(6):507-27 - PubMed
  26. J Biol Chem. 2007 Jul 13;282(28):20534-43 - PubMed
  27. Am J Respir Cell Mol Biol. 1994 Jan;10(1):38-47 - PubMed
  28. Curr Opin Pharmacol. 2009 Aug;9(4):375-83 - PubMed
  29. J Mol Biol. 2000 Apr 14;297(5):1183-94 - PubMed

Publication Types